Natera expands Austin operations, plans what it calls world's largest sequencing facility
Get Alerts NTRA Hot Sheet
Join SI Premium – FREE
Natera Inc. (NASDAQ: NTRA) announced plans to expand its North Austin headquarters campus with a new sequencing facility and additional laboratory space. The company stated the facility will have what it believes to be the largest sequencing capacity globally.
The expansion includes two projects at Natera's existing campus: a dedicated sequencing facility to increase capacity and additional space in a second building to support business growth. The company expects to create up to 400 new jobs across professional, laboratory, and operational roles through this expansion.
Natera reported that oncology testing volumes increased more than 54% year-over-year in the first quarter of 2026. The company's Signatera test is used by more than 50% of U.S. oncologists, according to the announcement. Signatera CDx recently became the first FDA-approved companion diagnostic in molecular residual disease testing.
"By expanding our lab space and sequencing capacity, we are investing in the infrastructure needed to serve more patients, support additional clinicians, and continue advancing personalized medicine at scale," said John Fesko, president and chief business officer of Natera.
The genetic testing company operates laboratories in Austin, Texas, San Carlos, California, and Boulder, Colorado through its subsidiary Foresight Diagnostics. Natera focuses on cell-free DNA testing and precision medicine for oncology, women's health, and organ health applications.
The information is based on a company press release statement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
- FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
- IES Holdings (IESC) files mixed shelf
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share